Compare · BDX vs ICUI
BDX vs ICUI
Side-by-side comparison of Becton Dickinson and Company (BDX) and ICU Medical Inc. (ICUI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and ICUI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 12.6x ICUI ($4.18B).
- BDX has hit the wire 9 times in the past 4 weeks while ICUI has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 15 for ICUI).
- Company
- Becton Dickinson and Company
- ICU Medical Inc.
- Price
- -
- -
- Market cap
- $52.78B
- $4.18B
- 1M return
- -
- +6.66%
- 1Y return
- -
- +37.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1992
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 15
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
ICU Medical Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest ICUI
- VP, General Counsel Sanzone Virginia Ruth sold $819,150 worth of shares (4,856 units at $168.69) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 14,604 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,116,675 worth of shares (6,381 units at $175.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 56,062 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,608,143 worth of shares (9,307 units at $172.79) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 62,443 units (SEC Form 4)
- ICU Medical to Participate in Upcoming Investor Conferences
- VP, GM-Infusion Capital Woolson Daniel sold $982,265 worth of shares (5,417 units at $181.33), decreasing direct ownership by 24% to 17,062 units (SEC Form 4)
- Chief Information Officer Sousa Ben sold $401,209 worth of shares (2,250 units at $178.32), decreasing direct ownership by 42% to 3,076 units (SEC Form 4)
- Chief Operating Officer Voigtlander Christian B. sold $1,633,404 worth of shares (8,929 units at $182.93), decreasing direct ownership by 19% to 37,377 units (SEC Form 4)
- Director Finney Elisha W sold $68,978 worth of shares (378 units at $182.48), decreasing direct ownership by 7% to 4,871 units (SEC Form 4)
- SEC Form 10-Q filed by ICU Medical Inc.
- ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits